Tenax Therapeutics, Inc. (TENX)
Stock Price:
$1.06 USD
-0.05 (-4.50%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
13.38M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-9.82M |
| Shares Out |
12.62M |
| EPS (ttm) |
-1.32 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$1.06 |
| Previous Close |
$1.11 |
| Change ($) |
-0.05 |
| Change (%) |
-4.50% |
| Day's Open |
1.11 |
| Day's Range |
1.05 - 1.11 |
| Day's Volume |
43,821 |
| 52-Week Range |
0.25 - 2.68 |
More Stats
| Market Cap |
13.38M |
| Enterprise Value |
9.07M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
12.62M |
| Float |
12.58M |
| EPS (basic) |
-1.36 |
| EPS (diluted) |
-1.32 |
| FCF / Share |
-0.90 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
223,309 |
| Short Ratio |
0.65 |
| Short % of Float |
1.78% |
| Beta |
2.31 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.62 |
| Revenue |
n/a |
| Operating Income |
-9.88M |
| Net Income |
-9.82M |
| Free Cash Flow |
-8.41M |
| Net Cash |
4.31M |
| Net Cash / Share |
0.34 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-82.27% |
| ROE |
-168.53% |
| ROIC |
1,595.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.22*
(298.11% upside)
Low
4.00
Current: $1.06
High
4.45
Target: 4.22
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | 0.05 | 0.29 | 1.23 | 0.42 | 0.32 | 0.01 |
| Revenue Growth | - | - | - | - | -82.93% | -76.6% | 197.33% | 28.75% | 3759.08% | - |
| Gross Profit | - | - | - | - | 0.05 | 0.16 | 1.19 | 0.36 | 0.10 | 0.01 |
| Operating Income | -8.56 | -6.89 | -9.21 | -52.65 | -14.82 | -16.61 | -5.19 | -8.22 | -10.56 | -10.20 |
| Net Income | -8.39 | -14.14 | -8.84 | -43.92 | -14.08 | -19.54 | -9.42 | -15.71 | -10.45 | -10.51 |
| Shares Outstanding | 6.20 | 1.56 | 1.41 | 1.41 | 1.40 | 0.47 | 0.08 | 0.06 | 0.06 | 0.05 |
| Earnings Per Share | -1.35 | -9.04 | -6.27 | -31.24 | -10.00 | -54.20 | -133.60 | -281.40 | -180.00 | -216.00 |
| Operating Cash Flow | -7.56 | -5.50 | -12.14 | -15.87 | -9.75 | -9.26 | -4.92 | -8.28 | -8.40 | -8.59 |
| Capital Expenditures | - | -0.01 | - | 0.07 | - | -0.01 | -0.01 | -0.01 | -0.24 | -0.24 |
| Free Cash Flow | -7.56 | -5.51 | -12.15 | -15.80 | -9.75 | -9.27 | -4.93 | -8.29 | -8.64 | -8.82 |
| Cash & Equivalents | 5.40 | 12.86 | 7.73 | 13.28 | 17.13 | 58.32 | 0.78 | 1.88 | 0.95 | 0.63 |
| Total Debt | 0.06 | - | - | - | 0.10 | 0.35 | 3.05 | 1.42 | 4.51 | 0.06 |
| Net Cash / Debt | 5.34 | 12.86 | 7.73 | 13.28 | 17.03 | 57.97 | -2.27 | 0.46 | -3.55 | 0.57 |
| Assets | 6.37 | 13.34 | 9.89 | 23.34 | 82.91 | 93.43 | 3.18 | 4.14 | 2.92 | 3.53 |
| Liabilities | 2.59 | 1.57 | 1.01 | 6.20 | 12.48 | 10.54 | 4.96 | 4.49 | 6.65 | 1.40 |
| Book Value | 3.77 | 11.77 | 8.88 | 17.14 | 70.43 | 82.89 | -1.78 | -0.35 | -3.72 | 2.13 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Tenax Therapeutics, Inc. |
| Country |
United States |
| Employees |
9 |
| CEO |
Anthony A. DiTonno |
Stock Information
| Ticker Symbol |
TENX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TENX |
Description
Tenax Therapeutics, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.